New Insights into Therapy-Induced Progression of Cancer
The malignant tumor is a complex heterogeneous set of cells functioning in a no less heterogeneous microenvironment. Like any dynamic system, cancerous tumors evolve and undergo changes in response to external influences, including therapy. Initially, most tumors are susceptible to treatment. Howeve...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-10-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/21/21/7872 |
_version_ | 1797549990057345024 |
---|---|
author | Polina V. Shnaider Olga M. Ivanova Irina K. Malyants Ksenia S. Anufrieva Ilya A. Semenov Marat S. Pavlyukov Maria A. Lagarkova Vadim M. Govorun Victoria O. Shender |
author_facet | Polina V. Shnaider Olga M. Ivanova Irina K. Malyants Ksenia S. Anufrieva Ilya A. Semenov Marat S. Pavlyukov Maria A. Lagarkova Vadim M. Govorun Victoria O. Shender |
author_sort | Polina V. Shnaider |
collection | DOAJ |
description | The malignant tumor is a complex heterogeneous set of cells functioning in a no less heterogeneous microenvironment. Like any dynamic system, cancerous tumors evolve and undergo changes in response to external influences, including therapy. Initially, most tumors are susceptible to treatment. However, remaining cancer cells may rapidly reestablish the tumor after a temporary remission. These new populations of malignant cells usually have increased resistance not only to the first-line agent, but also to the second- and third-line drugs, leading to a significant decrease in patient survival. Multiple studies describe the mechanism of acquired therapy resistance. In past decades, it became clear that, in addition to the simple selection of pre-existing resistant clones, therapy induces a highly complicated and tightly regulated molecular response that allows tumors to adapt to current and even subsequent therapeutic interventions. This review summarizes mechanisms of acquired resistance, such as secondary genetic alterations, impaired function of drug transporters, and autophagy. Moreover, we describe less obvious molecular aspects of therapy resistance in cancers, including epithelial-to-mesenchymal transition, cell cycle alterations, and the role of intercellular communication. Understanding these molecular mechanisms will be beneficial in finding novel therapeutic approaches for cancer therapy. |
first_indexed | 2024-03-10T15:23:00Z |
format | Article |
id | doaj.art-c4995a1ba51e4881bfe1b0af893699f1 |
institution | Directory Open Access Journal |
issn | 1661-6596 1422-0067 |
language | English |
last_indexed | 2024-03-10T15:23:00Z |
publishDate | 2020-10-01 |
publisher | MDPI AG |
record_format | Article |
series | International Journal of Molecular Sciences |
spelling | doaj.art-c4995a1ba51e4881bfe1b0af893699f12023-11-20T18:20:06ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-10-012121787210.3390/ijms21217872New Insights into Therapy-Induced Progression of CancerPolina V. Shnaider0Olga M. Ivanova1Irina K. Malyants2Ksenia S. Anufrieva3Ilya A. Semenov4Marat S. Pavlyukov5Maria A. Lagarkova6Vadim M. Govorun7Victoria O. Shender8Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow 119435, RussiaCenter for Precision Genome Editing and Genetic Technologies for Biomedicine, Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow 119435, RussiaLaboratory of Cell Biology, Federal Research and Clinical Center of Physical-Chemical Medicine of the Federal Medical and Biological Agency, Moscow 119435, RussiaCenter for Precision Genome Editing and Genetic Technologies for Biomedicine, Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow 119435, RussiaLaboratory of Cell Biology, Federal Research and Clinical Center of Physical-Chemical Medicine of the Federal Medical and Biological Agency, Moscow 119435, RussiaLaboratory of Membrane Bioenergetics, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow 117997, RussiaCenter for Precision Genome Editing and Genetic Technologies for Biomedicine, Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow 119435, RussiaLaboratory of Simple Systems, Federal Research and Clinical Center of Physical-Chemical Medicine of the Federal Medical and Biological Agency, Moscow 119435, RussiaCenter for Precision Genome Editing and Genetic Technologies for Biomedicine, Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow 119435, RussiaThe malignant tumor is a complex heterogeneous set of cells functioning in a no less heterogeneous microenvironment. Like any dynamic system, cancerous tumors evolve and undergo changes in response to external influences, including therapy. Initially, most tumors are susceptible to treatment. However, remaining cancer cells may rapidly reestablish the tumor after a temporary remission. These new populations of malignant cells usually have increased resistance not only to the first-line agent, but also to the second- and third-line drugs, leading to a significant decrease in patient survival. Multiple studies describe the mechanism of acquired therapy resistance. In past decades, it became clear that, in addition to the simple selection of pre-existing resistant clones, therapy induces a highly complicated and tightly regulated molecular response that allows tumors to adapt to current and even subsequent therapeutic interventions. This review summarizes mechanisms of acquired resistance, such as secondary genetic alterations, impaired function of drug transporters, and autophagy. Moreover, we describe less obvious molecular aspects of therapy resistance in cancers, including epithelial-to-mesenchymal transition, cell cycle alterations, and the role of intercellular communication. Understanding these molecular mechanisms will be beneficial in finding novel therapeutic approaches for cancer therapy.https://www.mdpi.com/1422-0067/21/21/7872cancer progressionchemotherapychemoresistancetumor microenvironmentintercellular communicationcell cycle |
spellingShingle | Polina V. Shnaider Olga M. Ivanova Irina K. Malyants Ksenia S. Anufrieva Ilya A. Semenov Marat S. Pavlyukov Maria A. Lagarkova Vadim M. Govorun Victoria O. Shender New Insights into Therapy-Induced Progression of Cancer International Journal of Molecular Sciences cancer progression chemotherapy chemoresistance tumor microenvironment intercellular communication cell cycle |
title | New Insights into Therapy-Induced Progression of Cancer |
title_full | New Insights into Therapy-Induced Progression of Cancer |
title_fullStr | New Insights into Therapy-Induced Progression of Cancer |
title_full_unstemmed | New Insights into Therapy-Induced Progression of Cancer |
title_short | New Insights into Therapy-Induced Progression of Cancer |
title_sort | new insights into therapy induced progression of cancer |
topic | cancer progression chemotherapy chemoresistance tumor microenvironment intercellular communication cell cycle |
url | https://www.mdpi.com/1422-0067/21/21/7872 |
work_keys_str_mv | AT polinavshnaider newinsightsintotherapyinducedprogressionofcancer AT olgamivanova newinsightsintotherapyinducedprogressionofcancer AT irinakmalyants newinsightsintotherapyinducedprogressionofcancer AT kseniasanufrieva newinsightsintotherapyinducedprogressionofcancer AT ilyaasemenov newinsightsintotherapyinducedprogressionofcancer AT maratspavlyukov newinsightsintotherapyinducedprogressionofcancer AT mariaalagarkova newinsightsintotherapyinducedprogressionofcancer AT vadimmgovorun newinsightsintotherapyinducedprogressionofcancer AT victoriaoshender newinsightsintotherapyinducedprogressionofcancer |